NEW YORK, September 17, 2013 /PRNewswire/ --
Today, Investors' Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Gilead Sciences Inc. (NASDAQ: GILD), Abbott Laboratories (NYSE: ABT), Actavis Inc. (NYSE: ACT), and Covidien plc (NYSE: COV). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Boston Scientific Corporation Research Report
On September 12, 2013, Boston Scientific Corporation (Boston Scientific) announced that it has completed enrollment in the EVOLVE II randomized, controlled clinical trial, a study designed to further assess the safety and effectiveness of the SYNERGY Stent System and support US Food and Drug Administration and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions. Kevin Ballinger, President, Interventional Cardiology, Boston Scientific, added, "Completing enrollment of EVOLVE II in just nine months is just one example of how Boston Scientific and the physician community are advancing cardiology together. The SYNERGY product underscores our ongoing commitment to delivering meaningful innovation to the interventional cardiology community and reinforces our position as a global leader in medical devices." The Company informed that the 1,684 Patients enrolled across 125 sites worldwide in the EVOLVE II trial will be followed for five years. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-13/BSX]
Gilead Sciences Inc. Research Report
On September 12, 2013, Gilead Sciences Inc. (Gilead) announced results from a Phase 2 study, evaluating an investigational once-daily tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. Gilead informed that at 48 weeks, a regiment of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg was found similar to Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the percentage of patients with HIV RNA levels less than 50 copies/mL, and was associated with more favorable renal and bone safety markers. Commenting on the results, Norbert W. Bischofberger, Phd, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer, said, "Based on these positive results, we believe that TAF has the potential to become a key component of next-generation single tablet regimens in HIV therapy. We are now completing enrollment of two Phase 3 clinical trials comparing a TAF-based regimen to Stribild in patients new to HIV treatment, and look forward to sharing initial results from these large-scale studies by the end of 2014." The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-13/GILD]
Abbott Laboratories Research Report
On September 12, 2013, Abbott Laboratories (Abbott) announced that it has been named as an Industry Group Leader in the 2013 Dow Jones Sustainability Index (DJSI). According to the Company, this is the ninth consecutive year that Abbott has made into the Dow Jones Sustainability World Index and North America Index. The Company informed that it has been also selected as leader in its specific DJSI industry sector, Health Care Equipment & Supplies, with overall score of 82, which was significantly higher than the average score of 39 for other companies in the sector. The Company further added that it also earned the highest scores across all three main areas of evaluation, including economic, environmental, and social performance. Katherine Pickus, Divisional Vice President, Global Citizenship and Policy at Abbott, said, "Abbott's strong performance in the DJSI is a reflection of the company's longstanding commitment to responsible and transparent business practices. Abbott strives to foster economic, environmental and societal well-being through our products, our core business operations and our partnerships with others." The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-13/ABT]
Actavis Inc. Research Report
On September 12, 2013, Actavis Inc. (Actavis) announced that it has launched Oxymorphone Hydrochloride Extended-release tablets 5mg, 10mg, 30 mg, and 40 mg. The Company informed that Actavis' ANDA product is the generic equivalent to the previously marketed formulation of Endo Health Solutions' (Endo) Opana ER - an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time. Actavis stated that Opana ER was voluntarily withdrawn from sale in 2012 by Endo. According to the Company, currently, Actavis is a defendant in a lawsuit filed by Endo alleging that Actavis' Oxymorphone Hydrochloride Extended-release product infringes certain of Endo's patents. The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-13/ACT]
Covidien plc Research Report
On September 12, 2013, Covidien plc (Covidien) announced its key strategic initiatives, growth opportunities, and innovations that are expected to drive the Company's growth in 2014 and beyond at a meeting held for the investment community. Covidien Chairman, President, and CEO Jose E. Almeida said, "Despite the challenging external environment, we are delivering a very solid performance in 2013. Our focus on growth, leverage and capital allocation will be the drivers of our future performance. We will make further investments to expand our capabilities, particularly in emerging markets, and to capitalize on the market opportunities across our business." The Company further informed that for full-year FY 2014, it anticipates net sales growth of 2% to 5% YoY. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-13/COV]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Investors' Reports